Introduction
Natural health products (NHPs), a broad category that includes vitamins, minerals, herbs, homeopathic remedies, traditional medicines, probiotics, amino acids and fatty acids, are used to maintain and promote health, as well as to prevent or treat illness. 1 Many consumers report using NHPs because they are perceived to be healthier or safer than conventional drugs. 2 A Health Canada survey found that 73% of Canadians have reported using at least 1 NHP, and 20% believe NHPs are without adverse effects. 2 As NHPs are available without a prescription, patients often use them to treat their medical conditions, based on advice obtained from the Internet, media sources and/or friends/ family. 3 Patients also do not consistently disclose NHP use to health care providers, nor are they routinely asked about such use. [4] [5] [6] This lack of communication may have serious implications; for example, some NHPs, such as kava, have been associated with hepatotoxicity, 7 and St. John's wort may interact with a number of prescription medicines that may lead to failed therapeutic outcomes or increased risk of toxicity. 8 Use of these products without health professional input could be inappropriate or lead to delayed recognition of adverse reactions if they occur.
Community Pharmacy SONAR (Study Of Natural health product Adverse Reactions) is a multicentre study investigating adverse events (AEs) associated with the use of prescription drugs, NHPs and their concurrent use through the implementation of active surveillance. Consenting patients who reported an AE while also taking an NHP (both alone or concurrently with prescription drugs) were contacted by a research pharmacist (CN) to collect a detailed medical history. Detailed methods are available elsewhere. 9 This study was approved by the Human Research Ethics Board at the University of Alberta. Here, we present a detailed case history of a SONAR study participant. The patient's medication history is presented in a stepwise fashion to illustrate what can be learned when a pharmacist further questions a patient about NHP use-the initial information available is typical of routine pharmacy practice; the subsequent additive information can be learned when additional details are sought by the pharmacist.
Case description
A 58-year-old woman presented to her community pharmacy to pick up a refill of a prescription medication. The patient's medical conditions included hypertension and osteopenia; she had also been diagnosed with "adrenal exhaustion" by her naturopath. The patient was an otherwise healthy nonsmoker, nondrinker who regularly exercised. No health concerns were raised with the pharmacist at the visit.
Patient's current medication history as listed on pharmacy computer record:
• Amlodipine 5 mg once daily Upon questioning the patient about her NHP use, using the screening questions from the CASEREPORT Community Pharmacy SONAR study ( Figure  1 ), the patient revealed taking additional health products that were previously unknown to the pharmacist.
Patient's self-reported current medication history after being prompted about NHP use at the counter by the pharmacist:
1. Amlodipine 2. Multivitamin 3. Fish oil 4. Calcium 5. Phytoestrogen
Using the same study form (Figure 1 ), the pharmacist then questioned the patient about whether she had experienced any adverse event(s) in the past month. The patient reported that she had been experiencing severely painful dyspepsia that often resulted in a complete cessation of normal daily activities until the pain subsided. This event first began 1 year before and was ongoing, occurring 1 to 5 times a month.
The patient agreed to participate in the Pharmacy SONAR study and signed written consent to be contacted for an in-depth interview by the study pharmacist (CN). During the interview, the patient was asked to gather all prescription drugs, over-the-counter products and NHPs that she was currently taking. This interview revealed that the patient was taking 24 NHPs along with her 1 prescription medication ( Table 1) .
Most NHPs were combination products that contained a total of more than 55 individual NHP ingredients. A number of these ingredients were included in more than 1 combination product ( Table 1) . A large proportion of the NHPs that the patient was taking had been purchased online "to maintain good health."
Discussion
Many patients cared for in community pharmacy settings take 1 or more prescription drugs while self-prescribing multiple other undisclosed health products. In combination, these products may provide more than the accepted daily doses of certain chemical or natural ingredients, increasing their risk of toxicity or interactions.
The patient described in this case report had been taking numerous NHPs for approximately 1 year, which coincides with the onset of her dyspepsia. With so many different products, and no further data available, this AE could not be attributed to any single product. Although some authoritative sources stating recommended daily doses of NHPs are available, we did not compare the daily doses the patient reported taking with these since it is unlikely that any source would recommend taking this number of products concurrently even at the recommended doses. This patient was informed by the study pharmacist about the possible risks of taking multiple health products concurrently and was advised to seek guidance from her pharmacist and/or physician.
This case highlights the risks of self-prescribed NHPs and the failure to disclose their use. 3, 5 When asked why they do not disclose complementary medicine use, patients report feeling that their health care providers will disapprove of the use of such products or not give their full attention to the topic, as well as the fear of losing access to NHPs. 3 Pharmacists should be aware of this and are encouraged to provide a Best Possible Medication History (BPMH) for all patients in their care. 10 The BPMH Guidelines for Medication Reconciliation distributed by the Ontario College of Pharmacists clearly indicate the need to specifically ask about NHP use in addition to prescription and overthe-counter drugs. 10 Busse et al. 11 found that while 41.5% of patients surveyed did not disclose NHP use to their physicians, the single most predictive factor to disclosing this information was their physician asking them specifically about NHP use. Community Pharmacy SONAR suggests a similar opportunity exists for pharmacists-of the 3000 patients screened thus far, none has refused to disclose NHP use to their pharmacists when asked. Effective communication does not mean that we have to agree with our patient's choices 12 ; rather, in opening discussion to inform patients, we will gain their trust in disclosing their health care choices in a nonjudgmental environment. Doing so will allow pharmacists to provide guidance to their patients that will reduce their risk of experiencing NHP and/or medicinerelated harm.
It is important for pharmacists and patients to remember that any substance that is pharmacologically active can also pose health risks (i.e., "natural" does not inherently mean "safe"). 3, 13 Approximately one-third of Canadians use 3 or more NHPs concurrently, in addition to nearly half of Canadians taking prescription drugs and NHPs together. 14, 15 The more health products a patient takes at the same time, the higher the theoretical risk of experiencing interactions and other adverse drug reactions. 13, 16 In the Community Pharmacy SONAR study, 7.5% of those patients taking prescription drugs and NHPs concurrently in Ontario reported having experienced an AE. 9
Conclusion
Many patients take multiple NHPs concurrently, as well as with concomitant prescription medicines, and without the advice of a health care provider. The case presented describes a patient who was consuming more than 55 individual NHP ingredients without any disclosure to her pharmacist or physician. The stepwise disclosure of NHP use in this case in response to further questions highlights the need for pharmacists to open the lines of communication surrounding NHP use with their patients to prevent unnecessary harm from occurring and to improve their patients' overall therapeutic outcomes. Incorporating the use of a systematic tool such as the one used in Pharmacy SONAR may be a helpful way for pharmacists to obtain a thorough disclosure from their patients surrounding NHP use and possible adverse reactions. 9 
